JW CreaGen, European Patent for Autoimmune Disease Treatment Manufacturing Technology
[Asia Economy Reporter Cho Hyun-ui] JW Shinyak announced on the 8th that its subsidiary JW CreaGene has proven the novelty of its dendritic cell therapy manufacturing technology effective for autoimmune diseases in Europe.
According to JW Shinyak, JW CreaGene received approval from the European Patent Office (EPO) for patent registration on the 'biopharmaceutical development technology using semi-mature dendritic cells.'
The patent relates to a method of producing semi-mature dendritic cells by treating immature dendritic cells with autoantigens and activating substances. It is a technology for developing treatments and vaccines (preventive therapeutics) for autoimmune diseases such as rheumatoid arthritis.
Dendritic cells play a role in either activating or suppressing immune cells depending on their maturation stage. Mature dendritic cells strengthen the weakened immune system of patients and instruct T cells to attack cancer cells, thus being used in anticancer vaccines. On the other hand, semi-mature dendritic cells have immune regulatory functions that control excessive immune responses and suppress immune cells attacking self-tissues, making them applicable for autoimmune disease treatment.
JW CreaGene is currently developing an immune disease treatment based on mature dendritic cell therapies for liver cancer (Phase 3 clinical trial), glioblastoma (Phase 1 and 2 clinical trials), and immature dendritic cell manufacturing technology. Following the approval from the European Patent Office, JW CreaGene plans to complete final patent acquisition within the year by undergoing individual entry procedures targeting major European countries.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- Despite Warnings of "Do Not Enter, You May Not Make It Out Alive"... Foreign Tourist Stranded After Unauthorized Climb on Jeju Sanbangsan
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Lee Kyung-jun, CEO of JW CreaGene, said, “We have secured patents not only in the anticancer vaccine field but also for dendritic cell manufacturing technology applicable to autoimmune disease treatments such as rheumatoid arthritis in advanced European markets. As our value is recognized in the global immune cell therapy market, we plan to focus the company's capabilities on successful commercialization.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
